High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

• Published in: JTO clinical and research reports 2022-06, Vol.3 (6), p.100328-100328, Article 100328
• Main Authors: Piper-Vallillo, A.J., Rotow, Julia K., Aredo, Jacqueline V., Shaverdashvili, Khvaramze, Luo, Jia, Carlisle, Jennifer W., Husain, Hatim, Muzikansky, Alona, Heist, Rebecca S., Rangachari, Deepa, Ramalingam, Suresh S., Wakelee, Heather A., Yu, Helena A., Sequist, Lecia V., Bauml, Joshua M., Neal, Joel W., Piotrowska, Zofia
• Format: Article
• Language: English
• Subjects: 160 mg; CNS progression; EGFR; Leptomeningeal progression; Original; Osimertinib
• ISSN: 2666-3643; 2666-3643
• DOI: 10.1016/j.jtocrr.2022.100328

This multicenter review evaluated the efficacy and safety of osimertinib dose escalation for central nervous system (CNS) progression developing on osimertinib 80 mg in EGFR-mutant NSCLC. Retrospective review identified 105 patients from eight institutions with advanced EGFR-mutant NSCLC treated with osimertinib 160 mg daily between October 2013 and January 2020. Radiographic responses were clinically assessed, and Kaplan-Meier analyses were used. We defined CNS disease control as the interval from osimertinib 160 mg initiation to CNS progression or discontinuation of osimertinib 160 mg. Among 105 patients treated with osimertinib 160 mg, 69 were escalated for CNS progression, including 24 treated with dose escalation alone (cohort A), 34 who received dose-escalated osimertinib plus concurrent chemotherapy and/or radiation (cohort B), and 11 who received osimertinib 160 mg without any prior 80 mg exposure. The median duration of CNS control was 3.8 months (95% confidence interval [CI], 1.7–5.8) in cohort A, 5.1 months (95% CI, 3.1–6.5) in cohort B, and 4.2 months (95% CI 1.6–not reached) in cohort C. Across all cohorts, the median duration of CNS control was 6.0 months (95% CI, 5.1–9.0) in isolated leptomeningeal progression (n = 27) and 3.3 months (95% CI, 1.0–3.1) among those with parenchymal-only metastases (n = 23). Patients on osimertinib 160 mg experienced no severe or unexpected side effects. Among patients with EGFR-mutant NSCLC experiencing CNS progression on osimertinib 80 mg daily, dose escalation to 160 mg provided modest benefit with CNS control lasting approximately 3 to 6 months and seemed more effective in patients with isolated leptomeningeal CNS progression.